FDA To Issue Remarketer Labeling Regs, Monitor Registration System
This article was originally published in The Gray Sheet
Device remarketers that label serviced devices as "ready for clinical use" under a recently proposed voluntary registration system will be subject to FDA enforcement action if the devices do not meet performance specifications, according to FDA staffers.
You may also be interested in...
FDA's revised policy on reprocessing of disposable medical devices would require manufacturers seeking to label a product as single-use only to submit data demonstrating that it cannot adequately be reprocessed, FDA staffers report.
Device remarketers and servicers should indicate whether reserviced devices are "ready for clinical use" or "must be checked for proper performance and safety" under a proposed voluntary registration system issued Sept. 9 by an industry task force coordinated by the Association for the Advancement of Medical Instrumentation.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.